<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-L69K8W8H</identifier><date>2022</date><creator>Borštnar, Simona</creator><creator>Dobovišek, Luka</creator><creator>Gašljević, Gorana</creator><creator>Ovčariček, Tanja</creator><creator>Stefanovski, Dimitar</creator><relation>documents/doc/L/URN_NBN_SI_doc-L69K8W8H_001.pdf</relation><relation>documents/doc/L/URN_NBN_SI_doc-L69K8W8H_001.txt</relation><format format_type="type">article</format><format format_type="extent">Str. 129-130</format><identifier identifier_type="COBISSID_HOST">139412995</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-L69K8W8H</identifier><language>slv</language><publisher publisher_location="Ljubljana">Kancerološko združenje Slovenskega zdravniškega društva</publisher><publisher publisher_location="Ljubljana">Onkološki inštitut</publisher><source>34. onkološki vikend</source><rights>InC</rights><subject language_type_id="slv">kemoterapija</subject><subject language_type_id="slv">onkologija</subject><subject language_type_id="slv">rak dojke</subject><title>podatki iz realnega sveta</title><title>Zdravljenje razsejanega, trojno negativnega raka dojk z atezolizumabom in nab-paklitakselom</title></Record>